Bayer invests USD 50 Million in eGenesis Series B financing round
Investment to support development of human-compatible xeno organs to address the global organ shortage crisis
11-Nov-2019 -
eGenesis, a biotechnology company utilizing breakthrough gene editing technologies for the development of effective human-compatible organs to address the global organ shortage, successfully completed a USD 100 million Series B financing. The financing was led by Fresenius Medical Care Ventures ...
gene editing
organ transplantation
organs
+2